The 4 million Americans affected by Hepatitis C may have some good news coming to them today: Vertex Pharmaceuticals' experimental drug, telaprevir, has performed even better than expected in clinical trials.
Three quarters of patients in the trial who got 12 weeks of the drug were found to have no trace of the virus in their blood for 24 weeks following treatment. This is considered a sustained virulogic response and the closest thing to a cure that currently exists.
"The community hopes that if telaprevir is approved by the F.D.A. that it will be accessible and affordable to everyone," Lorren Sandt, chairwoman of the National Viral Hepatitis Roundtable, told the New York Times. As of now, the drug is expected to cost tens of thousands of dollars for a course of treatment.